4 results on '"Ana Maria Ornstein"'
Number of results to display per page
Search Results
2. Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models
- Author
-
Carolina Cristina, Guillermina María Luque, Gianina Demarchi, Felicitas Lopez Vicchi, Lautaro Zubeldia-Brenner, Maria Ines Perez Millan, Sofia Perrone, Ana Maria Ornstein, Isabel M. Lacau-Mengido, Silvia Inés Berner, and Damasia Becu-Villalobos
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
The role of angiogenesis in pituitary tumor development has been questioned, as pituitary tumors have been usually found to be less vascularized than the normal pituitary tissue. Nevertheless, a significantly higher degree of vasculature has been shown in invasive or macropituitary prolactinomas when compared to noninvasive and microprolactinomas. Many growth factors and their receptors are involved in pituitary tumor development. For example, VEGF, FGF-2, FGFR1, and PTTG, which give a particular vascular phenotype, are modified in human and experimental pituitary adenomas of different histotypes. In particular, vascular endothelial growth factor, VEGF, the central mediator of angiogenesis in endocrine glands, was encountered in experimental and human pituitary tumors at different levels of expression and, in particular, was higher in dopamine agonist resistant prolactinomas. Furthermore, several anti-VEGF techniques lowered tumor burden in human and experimental pituitary adenomas. Therefore, even though the role of angiogenesis in pituitary adenomas is contentious, VEGF, making permeable pituitary endothelia, might contribute to adequate temporal vascular supply and mechanisms other than endothelial cell proliferation. The study of angiogenic factor expression in aggressive prolactinomas with resistance to dopamine agonists will yield important data in the search of therapeutical alternatives.
- Published
- 2014
- Full Text
- View/download PDF
3. Corrigendum to 'Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models'
- Author
-
Guillermina Maria Luque, Lautaro Zubeldia-Brenner, I.M. Lacau-Mengido, Sofia Perrone, Maria Ines Perez Millan, Silvia Inés Berner, Carolina Cristina, Gianina Demarchi, Felicitas Lopez Vicchi, Ana Maria Ornstein, and Damasia Becu-Villalobos
- Subjects
Endocrinology ,Human studies ,Endocrine and Autonomic Systems ,Angiogenesis ,business.industry ,Endocrinology, Diabetes and Metabolism ,Mutant ,Cancer research ,Medicine ,Corrigendum ,RC648-665 ,business ,Diseases of the endocrine glands. Clinical endocrinology - Abstract
The role of angiogenesis in pituitary tumor development has been questioned, as pituitary tumors have been usually found to be less vascularized than the normal pituitary tissue. Nevertheless, a significantly higher degree of vasculature has been shown in invasive or macropituitary prolactinomas when compared to noninvasive and microprolactinomas. Many growth factors and their receptors are involved in pituitary tumor development. For example, VEGF, FGF-2, FGFR1, and PTTG, which give a particular vascular phenotype, are modified in human and experimental pituitary adenomas of different histotypes. In particular, vascular endothelial growth factor, VEGF, the central mediator of angiogenesis in endocrine glands, was encountered in experimental and human pituitary tumors at different levels of expression and, in particular, was higher in dopamine agonist resistant prolactinomas. Furthermore, several anti-VEGF techniques lowered tumor burden in human and experimental pituitary adenomas. Therefore, even though the role of angiogenesis in pituitary adenomas is contentious, VEGF, making permeable pituitary endothelia, might contribute to adequate temporal vascular supply and mechanisms other than endothelial cell proliferation. The study of angiogenic factor expression in aggressive prolactinomas with resistance to dopamine agonists will yield important data in the search of therapeutical alternatives.
- Published
- 2020
- Full Text
- View/download PDF
4. Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models
- Author
-
Felicitas Lopez Vicchi, Ana Maria Ornstein, I.M. Lacau-Mengido, Silvia Inés Berner, Guillermina Maria Luque, Maria Ines Perez Millan, Carolina Cristina, Damasia Becu-Villalobos, Sofia Perrone, Gianina Demarchi, and Lautaro Zubeldia-Brenner
- Subjects
medicine.medical_specialty ,CIENCIAS MÉDICAS Y DE LA SALUD ,Angiogenesis ,Endocrinology, Diabetes and Metabolism ,Review Article ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Dopamine agonist ,ANGIOGENESIS ,chemistry.chemical_compound ,Endocrinology ,PITUITARY ,Internal medicine ,ADENOMAS ,medicine ,Receptor ,lcsh:RC648-665 ,Endocrine and Autonomic Systems ,business.industry ,Fibroblast growth factor receptor 1 ,Pituitary tumors ,purl.org/becyt/ford/3.1 [https] ,Bioquímica y Biología Molecular ,medicine.disease ,VEGF ,Endothelial stem cell ,Vascular endothelial growth factor ,Medicina Básica ,chemistry ,purl.org/becyt/ford/3 [https] ,business ,medicine.drug ,Endocrine gland - Abstract
The role of angiogenesis in pituitary tumor development has been questioned, as pituitary tumors have been usually found to be less vascularized than the normal pituitary tissue. Nevertheless, a significantly higher degree of vasculature has been shown in invasive or macropituitary prolactinomas when compared to noninvasive and microprolactinomas. Many growth factors and their receptors are involved in pituitary tumor development. For example, VEGF, FGF-2, FGFR1, and PTTG, which give a particular vascular phenotype, are modified in human and experimental pituitary adenomas of different histotypes. In particular, vascular endothelial growth factor, VEGF, the central mediator of angiogenesis in endocrine glands, was encountered in experimental and human pituitary tumors at different levels of expression and, in particular, was higher in dopamine agonist resistant prolactinomas. Furthermore, several anti-VEGF techniques lowered tumor burden in human and experimental pituitary adenomas. Therefore, even though the role of angiogenesis in pituitary adenomas is contentious, VEGF, making permeable pituitary endothelia, might contribute to adequate temporal vascular supply and mechanisms other than endothelial cell proliferation. The study of angiogenic factor expression in aggressive prolactinomas with resistance to dopamine agonists will yield important data in the search of therapeutical alternatives. Fil: Cristina, Silvia Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires. Universidad Nacional del Noroeste de la Provincia de Buenos Aires. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; Argentina Fil: Luque, Guillermina Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Demarchi, Gianina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires. Universidad Nacional del Noroeste de la Provincia de Buenos Aires. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; Argentina Fil: López Vicchi, María Felicitas. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Zubeldia Brenner, Lautaro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Pérez Millán, María Inés. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Perrone, Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires. Universidad Nacional del Noroeste de la Provincia de Buenos Aires. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; Argentina Fil: Ornstein, Ana Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Lacau, Isabel Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Berner, Silvia Inés. Clínica Santa Isabel; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital Oftalmológico Santa Lucía; Argentina Fil: Becu, Damasia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.